IDBS and Titian to Provide Complete Solution for Drug Discovery Market
News Oct 03, 2007
IDBS has announced a strategic partnership with Titian Software Ltd (London, UK).
Titian specializes in sample management and provides inventory management solutions to enable the supply of compounds, reagents and biological samples to vital scientific research processes. Titian has worked with a broad range of customers, including major global pharmaceutical and smaller screening organizations.
IDBS and Titian have entered into a strategic collaboration whereby they will provide a comprehensive, customer-focused solution for life science organizations. IDBS’ applications will interact with Titian’s Mosaic inventory management system to streamline customer workflow, increasing screening efficiency, throughput and data integrity.
“This agreement represents a great opportunity to tailor our products towards our customers’ needs. IDBS’ industry-leading data management capabilities will complement our expertise in inventory management, strengthening our value proposition to the life science industry,” commented Richard Fry, co-founder and Commercial Director of Titian.
Neil Kipling, founder and CEO of IDBS, commented: “Increasingly our customers have indicated a need for flexible inventory management. Our customers will benefit from the direct integration with ActivityBase, providing them with the best possible solution for managing their screening and discovery data.”
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE